Positive Biomarker Results from PROTECT Trial
Allergy Therapeutics PLC (AIM: AGY) has announced promising biomarker results from its PROTECT Phase I/IIa trial for VLP Peanut, indicating a strong immunomodulating response in peanut-allergic subjects. The trial demonstrated significant reductions in basophil sensitivity and IgE-Fab binding to the primary allergen Ara h2, with the highest dose achieving statistical significance. Specifically, reductions of 376% (p=0.003) for whole peanut extract and 489% (p=0.04) for Ara h2 were observed compared to placebo. Additionally, a dose-dependent increase in Ara h2-specific IgG was noted, alongside a reduction in wheal diameter after skin prick testing. These findings suggest that VLP Peanut could represent a transformative short-course treatment option for peanut allergies, a significant advancement given the limitations of current therapies.
The PROTECT trial, which completed its final dosing in December 2025, included a comprehensive panel of biomarkers to assess efficacy. The results indicate a consistent immunomodulating response across all peanut-allergic subjects treated with VLP Peanut. Notably, the trial's outcomes have garnered positive commentary from leading immunology experts, who highlighted the potential of VLP Peanut to alter the treatment landscape for peanut allergies. The trial's design, which involved three injections over a two to three-month period, contrasts sharply with traditional oral immunotherapy approaches that require daily administration for extended periods. This innovative treatment paradigm could significantly enhance patient compliance and outcomes.
From a financial perspective, Allergy Therapeutics has a market capitalisation of approximately £100 million. The company has been actively pursuing funding to support its clinical programs, with a cash balance reported at £15 million as of the latest quarterly update. Given the current burn rate of £3 million per quarter, the company has an estimated funding runway of five months. This raises concerns regarding the sufficiency of existing capital to support the anticipated Phase IIb trial, which aims to establish dose-range and efficacy through food challenge assessments. The potential need for additional capital raises could introduce dilution risk for existing shareholders, particularly if the company seeks to finance its operations through equity issuance.
In terms of valuation, Allergy Therapeutics is currently trading at an enterprise value of approximately £85 million. When compared to direct peers such as Allergy Therapeutics (AIM: AGY), which operates in a similar space but at a different stage, and other small-cap biotechnology firms focused on allergy treatments, the valuation metrics suggest that AGY is positioned competitively. For instance, peer companies in the allergy immunotherapy sector are often valued at EV per NPV multiples ranging from 5x to 10x, depending on their clinical stage and market potential. Given the promising results from the PROTECT trial, Allergy Therapeutics may be able to command a higher valuation multiple if it successfully progresses through subsequent trial phases.
The execution track record of Allergy Therapeutics has been mixed, with prior announcements often highlighting ongoing clinical developments without clear timelines for progression. However, the current results from the PROTECT trial appear to align with management's previous guidance regarding the potential of VLP Peanut. The company has historically met its trial milestones, but the upcoming Phase IIb trial will be critical in determining the product's clinical viability and market potential. A specific risk highlighted by this announcement is the potential for regulatory hurdles as the company seeks to advance its clinical program in a competitive landscape dominated by established therapies.
Looking ahead, the next measurable catalyst for Allergy Therapeutics will be the initiation of the Phase IIb trial, which is expected to commence in the second half of 2026. This trial will be pivotal in establishing the efficacy of VLP Peanut through food challenge assessments, a critical step in the regulatory approval process. The outcomes of this trial will likely influence investor sentiment and the company's ability to secure additional funding.
In conclusion, the announcement of positive biomarker results from the PROTECT trial represents a significant development for Allergy Therapeutics, suggesting that VLP Peanut has the potential to transform the treatment landscape for peanut allergies. However, the company's current financial position raises questions about funding sufficiency and potential dilution risks. Overall, this announcement can be classified as significant, given its implications for clinical development and the potential to enhance the company's valuation in the biotechnology sector.